JLPC(SH:600513) Zheng Quan Zhi Xing·2025-06-04 09:18Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. has received the Drug Registration Certificate for its product, Dopamine Hydrochloride Injection, which is expected to enhance the company's product line and market competitiveness [1][2]. Group 1: Drug Registration Details - The Drug Registration Certificate pertains to Dopamine Hydrochloride Injection, classified as a Class 3 chemical drug and a prescription medication [1][2]. - The product specifications include a dosage form of injection with a concentration of 100 mg in a 5 ml vial [1]. - The approval number for the registration is CYHS2303423, and the certificate number is 2025S01492 [1]. Group 2: Market Context and Financial Impact - The Dopamine Hydrochloride Injection is used for treating heart failure due to decreased myocardial contractility in organic heart disease, with a reported sales figure of 444 million RMB in 2024 [2]. - The company has invested approximately 7 million RMB in research and development for this product as of the announcement date [2]. - The acquisition of the Drug Registration Certificate is not expected to have a significant impact on the company's recent operating performance [2]. Group 3: Company Development - The company has obtained a total of 7 production licenses and 1 clinical license in 2025 [2]. - The approval of the Drug Registration Certificate signifies that the product has passed the consistency evaluation of generic drug quality and efficacy [2].